Modifiedblue cross blue shield - louisianaPolicy AHS - G2008 - Prostate Specific Antigen (PSA) Testing

Prostate Specific Antigen (PSA) Testing

Customize your policy alerts

Sign up for blue cross blue shield - louisiana Policy AHS - G2008 - Prostate Specific Antigen (PSA) Testing alerts

Get alerted when Policy AHS - G2008 - Prostate Specific Antigen (PSA) Testing changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Coverage and clinical guidance for use of total PSA and select PSA-related tests for screening, diagnosis, monitoring, and treatment management of prostate cancer for individuals with a prostate; includes age- and risk-based screening intervals and tests that do not meet coverage criteria.

Policy Summary

Payerblue cross blue shield - louisiana

PolicyProstate Specific Antigen (PSA) Testing

Policy CodePolicy AHS - G2008 - Prostate Specific Antigen (PSA) Testing

Change TypeClinical advisory reviewrevised coverage criteria and percent free PSA guidance

Effective DateSep 15, 2026

Last ReviewSep 15, 2026

Next Review DateSep 15, 2026

Key ActionDocument required clinical documentation of age, risk status, prior PSA results, and shared decision-making when ordering PSA testing.

SourceLink

POLICY UPDATE CHANGES

CC1 edited for clarity, added 'initial', now reads: '1) For average-risk individuals 45 years of age and older (see Note 1), initial screening for prostate cancer with the total prostate-specific antigen (PSA) test MEETS COVERAGE CRITERIA.'

Updates made to CC4 and CC5 to align with NCCN guideline updates for percent free PSA.

CC4 edited previously (09/01/2025) to remove percent free PSA as a standard follow-up and moved subcriteria into Note 2; CC5 revised to refer to 'initial negative biopsy' and complexed PSA moved to its own criterion.

45 yrsAvg-risk initial screening age

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Modifiedblue cross blue shield - louisianaPolicy AHS - G2008 - Prostate Specific Antigen (PSA) Testing

Prostate Specific Antigen (PSA) Testing

Customize your policy alerts

Sign up for blue cross blue shield - louisiana Policy AHS - G2008 - Prostate Specific Antigen (PSA) Testing alerts

Get alerted when Policy AHS - G2008 - Prostate Specific Antigen (PSA) Testing changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payerblue cross blue shield - louisiana

PolicyProstate Specific Antigen (PSA) Testing

Policy CodePolicy AHS - G2008 - Prostate Specific Antigen (PSA) Testing

Change TypeClinical advisory reviewrevised coverage criteria and percent free PSA guidance

Effective DateSep 15, 2026

Last ReviewSep 15, 2026

Next Review DateSep 15, 2026

Key ActionDocument required clinical documentation of age, risk status, prior PSA results, and shared decision-making when ordering PSA testing.

SourceLink

POLICY UPDATE CHANGES

Updates made to CC4 and CC5 to align with NCCN guideline updates for percent free PSA.

45 yrsAvg-risk initial screening age

Earlier screening for high-risk

>3 ng/mLElevated PSA threshold (<76)

1–4 yrsRepeat intervals (age-based)

3CPT/HCPCS codes listed

09/15/2026Last revision

Coverage Criteria for PSA Testing

inv-01: Screening: Initial and Annual

Covered when the following age- and risk-based criteria are met

Initial and annual screening: Initial screening with total PSA meets coverage for average-risk individuals 45 years and older; annual screening meets coverage for individuals 40 years and older when any of: African ancestry, germline mutation(s) that increase prostate cancer risk, or a suspicious family history.age- and risk-based

See Note 1 for guidance on testing above age 75; documentation should support age and risk status.

inv-02: Repeat screening intervals

Covered when repeat screening frequency criteria are met

Repeat screening by prior PSA and age: For individuals with prior total PSA results, repeat total PSA testing meets coverage with these frequencies: (a) age <76 years and total PSA <1 ng/mL with normal DRE (if done): repeat every 2–4 years; (b) age <76 years and total PSA 1–3 ng/mL with normal DRE (if done): repeat every 1–2 years; (c) age >75 years and total PSA <4 ng/mL with normal DRE (if done) and no other indications for biopsy: repeat in select patients at 1–3 year intervals.PSA ranges and age

DRE if done; select patients for >75; see Note 1 for life-expectancy considerations.

inv-03: Follow-up after elevation or suspicious DRE

Covered for follow-up after elevated or suspicious findings

Short-term follow-up after elevation or suspicious DRE: For individuals who have elevated PSA (see Note 2) or a suspicious DRE, a follow-up total PSA in 6–12 months meets coverage.6-12 months

Note 2 defines elevated PSA; percent free PSA was removed as standard immediate follow-up in 09/01/2025 (see revision history).

inv-04: Diagnostic and monitoring indications

Covered uses of total PSA

Diagnostic and disease management uses: Total PSA testing meets coverage for: (a) initial diagnosis in individuals with signs or symptoms of prostate cancer; (b) follow-up of individuals with current or prior prostate cancer; (c) ongoing monitoring after tumor resection or prostatectomy; (d) monitoring response to therapy; and (e) detecting disease recurrence.clinical indication

See Note 3 for examples of signs/symptoms; documentation should support indication.

inv-05: Percent free PSA after negative biopsy

Covered follow-up biomarker

Percent free PSA after initial negative biopsy: When total PSA is elevated and an initial prostate biopsy is negative, follow-up testing with percent free PSA meets coverage; testing should be performed no more often than follow-up total PSA.no more frequent than follow-up total PSA

Policy revised 09/01/2025 to reference 'initial negative biopsy' and 09/15/2026 updates aligned with guideline changes.

inv-06: MSK age-based screening recommendations

MSK screening guidance by age band (for men with >=10 year life expectancy)

Ages 45-49: Consider baseline PSA. If PSA >=3 ng/mL: repeat and consider secondary testing (imaging or biomarker) if still >=3; if PSA 1–3 ng/mL: repeat in 2–4 years (repeat in ~2 years if closer to 3); if PSA <1 ng/mL: repeat between ages 51–55.PSA categories as stated

Applies to men with expected life expectancy of at least ten years.

Ages 50-59: Consider PSA screening. If PSA >=3 ng/mL: repeat and consider secondary testing if persistent; if PSA 1–3 ng/mL: repeat in 2–4 years; if PSA <1 ng/mL: repeat at age 60.PSA categories as stated

Ages 60-70: Consider PSA screening. If PSA >=3 ng/mL: repeat and consider secondary testing if persistent; if PSA 1–3 ng/mL: repeat in 2–4 years; if PSA <1 ng/mL: discontinue screening.PSA categories as stated

inv-07: NCCN: baseline testing and follow-up

NCCN recommendations for baseline testing and follow-up stratified by risk

Average risk (45-75): Offer baseline PSA with DRE for healthy, well-informed individuals aged 45–75; confirm elevated PSA with repeat testing; if PSA <1 ng/mL repeat every 2–4 years; if PSA 1–3 ng/mL repeat every 1–2 years; if PSA >3 ng/mL or very suspicious DRE consider biopsy after confirmation.PSA categories as stated

Panel supports screening to age 75 and continuation only in very healthy patients; consider patient factors.

High risk (African ancestry, concerning family history, germline mutations): Consider baseline testing starting at age 40; consider annual screening; otherwise apply the same PSA thresholds and intervals as the average-risk group.

Patients >75: Select patients over 75 may continue repeat testing at 1–3 year intervals if PSA <4 ng/mL, DRE normal, and no other indications for biopsy; if PSA >4 ng/mL or very suspicious DRE, repeat PSA/DRE and pursue workup (consider mpMRI and biomarkers when deciding about biopsy after negative MRI).PSA <4 vs >4 ng/mL

inv-08: AUA/SUO: screening and monitoring

AUA/SUO recommendations emphasizing shared decision-making and screening intervals

Shared decision-making: Clinicians should engage in shared decision-making with eligible patients and proceed based on patient values and preferences.

Document shared decision-making in the medical record.

Screening test and intervals: Use PSA as the first-line screening test. Offer baseline PSA at ages ~45–50 (conditional) and offer screening every 2–4 years for ages 50–69; offer baseline screening beginning at 40–45 for increased-risk individuals.

Intervals may be personalized based on risk and patient preference.

Repeat elevated PSA: Repeat PSA prior to using a secondary biomarker, imaging, or proceeding to biopsy; PSA velocity should not be used as the sole indication for secondary testing.

inv-09: ACS, NCI, ESMO/EAU positions

Other society positions

ACS: Recommend informed discussion before screening; begin at 50 for average risk, 45 for increased risk, and 40 for highest risk; interval based on initial PSA (<2.5 ng/mL => every 2 years; >=2.5 ng/mL => annually); avoid screening if life expectancy <10 years.2.5 ng/mL threshold for interval

Emphasize patient values and repeat counseling as new evidence emerges.

NCI: Finds insufficient evidence that PSA-based screening reduces mortality and highlights harms including overdiagnosis and treatment-related permanent side effects.

Supports caution in population screening and weighing harms vs benefits.

ESMO/EAU: Generally recommend against population-based screening; favor risk-adapted strategies with specific age/risk thresholds and stopping screening based on limited life expectancy (eg, <10 years) or advanced age (eg, >70).life expectancy thresholds

inv-10: Coverage criteria revisions and key covered/not-covered items

Summarized covered criteria revisions from review notes

CC1 - Initial screening (revised): For average-risk individuals 45 years of age and older (see Note 1), initial screening for prostate cancer with the total PSA test MEETS COVERAGE CRITERIA.age >=45

Revised 09/15/2026; 'initial' wording added.

CC4 - Follow-up for elevated PSA (revised): For individuals who have elevated PSA (see Note 2) or a suspicious DRE, a follow-up in 6-12 months with total PSA MEETS COVERAGE CRITERIA.interval 6-12 months

CC4 edited 09/01/2025 to remove percent free PSA as standard follow-up; Note 2 defines elevated PSA.

CC5 - Percent free PSA after initial negative biopsy (revised): For individuals who have elevated total PSA and who had an initial negative biopsy, follow-up testing (no more often than follow-up total PSA) with percent free PSA MEETS COVERAGE CRITERIA.

Percent free PSA testing (%fPSA or free-to-total PSA ratio) and complexed PSA assays are explicitly identified in the policy as tests that do not meet coverage criteria when used as first-line routine screening. The policy lists: (a) percent free PSA as a first-line screening test for prostate cancer, (b) percent free PSA or free-to-total PSA ratio for routine screening of prostate cancer, and (c) complexed PSA testing as not meeting coverage criteria.

Society guidance and evidence summaries cited in the policy recommend limiting screening for individuals with limited life expectancy and caution against population-based screening. The ACS and ESMO/EAU advise against screening when life expectancy is less than 10 years (ACS/ESMO) or 15 years (EAU risk-adapted recommendation), and emphasize individualized discussion of benefits and harms prior to testing. The NCI concludes the evidence is insufficient to demonstrate a mortality benefit from PSA-based screening and highlights significant potential harms such as overdiagnosis and treatment-related side effects.

The policy revision history documents that percent free PSA was removed as a standard routine follow-up screening measure and that percent free PSA and complexed PSA were moved to the list of tests that do not meet coverage criteria for first-line screening. The 09/01/2025 revision clarified that follow-up use of percent free PSA is restricted to specific settings (for example, after an initial negative biopsy) and reaffirmed that percent free PSA or free-to-total PSA ratio and complexed PSA testing do not meet coverage criteria when used routinely for screening.

Requests for percent free PSA or complexed PSA when intended as first-line routine screening are not covered under this policy. The policy explicitly lists these assays among the tests that "DOES NOT MEET COVERAGE CRITERIA," noting that percent free PSA as a first-line screening test, percent free or free-to-total PSA ratio for routine screening, and complexed PSA testing are not eligible for coverage in that indication.

The policy references the NCI and major society guidance when explaining the balance of benefits and harms for PSA-based screening. The NCI states that current evidence is insufficient to show a mortality benefit and documents harms including overdiagnosis and treatment-related permanent side effects. ESMO and EAU recommend against population-based screening because harms may outweigh benefits and advise risk-adapted screening strategies that consider life expectancy and individualized counseling.

Consistent with the literature review and recent policy revisions, percent free PSA testing and complexed PSA testing are designated as not meeting coverage criteria when used as first-line routine screening. The policy allows percent free PSA only in defined secondary roles (for example, follow-up after an initial negative biopsy) and otherwise classifies these variants as not covered for initial population screening due to limited supporting evidence.

Procedure Codes and Thresholds

Applicable CPT/HCPCS Procedure CodesCPT

84152	Prostate specific antigen (PSA); complexed (direct measurement)
84153	Prostate specific antigen (PSA); total
84154	Prostate specific antigen (PSA); free
G0103	Prostate cancer screening; prostate specific antigen test (PSA)

Elevated PSA thresholds

Elevated PSA — age <76Total PSA > 3 ng/mL

Elevated PSA — age ≥76Total PSA ≥ 4 ng/mL

Note contextDefinitions from policy Note 2 (thresholds trigger further evaluation)

PSA level categories

PSA category: <1 ng/mLLowest-risk category; retest interval typically 2–4 years (or per age-specific guidance)

PSA category: 1–3 ng/mLIntermediate category; retest interval typically 1–2 years

PSA category: ≥3 ng/mL

Provider Actions, Documentation & Billing Guidance

Prior Authorization

Prior authorization: none stated

No prior authorization requirements for PSA testing are stated in this policy document.

Prior Authorization

No prior authorization specified

The document does not specify any prior authorization requirements for PSA testing in the excerpted policy.

Billing Rule

Procedure code references (PSA)

Background and Clinical Context

Prostate-specific antigen (PSA) is a glycoprotein produced by normal and neoplastic prostate tissue and circulates in serum as free and bound forms. Total PSA assays measure the combined free and bound fractions and are used across clinical settings for screening, diagnosis, monitoring response to therapy, and detecting recurrence. Limitations of PSA testing include lack of cancer specificity and the potential for overdiagnosis and overtreatment, which underpin the policy’s selective coverage approach.

Definitions and Acronyms

Total PSA / Free PSA

Total PSAMeasures the amount of all PSA identified in serum, including bound (majority) and free forms

Free PSAThe unbound (enzymatically inactive) fraction of PSA circulating in serum; expressed as a proportion of total PSA

Clinical noteTotal vs free PSA proportions have been used to improve specificity for prostate cancer detection

Acronyms

DREDigital rectal examination

PHIProstate Health Index

PSA

Policy Revision History

2026-09-15clinical_review_and_revisionLatest

Clinical Advisory Board review and literature update resulted in edits to coverage criteria including adding the term 'initial' to CC1 and updates to CC4 and CC5 to align percent free PSA guidance with NCCN, and updates to background, guidelines, and references.

2025-09-01coverage_criteria_revision

Revised CC4 to remove percent free PSA as standard follow-up and moved subcriteria into Note 2; CC5 changed to reference 'initial negative biopsy'; CC7 reorganized to explicitly list percent free PSA and complexed PSA as not meeting coverage criteria.

Policy Summary

Payerblue cross blue shield - louisiana

PolicyProstate Specific Antigen (PSA) Testing

Policy CodePolicy AHS - G2008 - Prostate Specific Antigen (PSA) Testing

Change TypeClinical advisory reviewrevised coverage criteria and percent free PSA guidance

Effective DateSep 15, 2026

Last ReviewSep 15, 2026

Next Review DateSep 15, 2026

Key ActionDocument required clinical documentation of age, risk status, prior PSA results, and shared decision-making when ordering PSA testing.

SourceLink

On This Page

Ages 71-75: Use shared decision-making; continue testing only if PSA is elevated (>3 ng/mL) and health is good; personalize based on prior PSA and overall health.PSA >3 ng/mL relevant

Ages >=76: PSA testing is rarely helpful; discuss with patient and base decision on prior PSA and health status.

Consider discontinuing screening when clinically appropriate.

Recommend offering testing only to selected age/risk groups (e.g., >45 or >50 depending on risk).

no more often than follow-up total PSA

CC5 revised 09/01/2025 to reference 'initial negative biopsy'.

Not covered items (as of 09/01/2025): Percent free PSA as a first-line screening test; percent free or free-to-total PSA ratio for routine screening; complexed PSA testing.n/a

Complexed PSA explicitly listed as not meeting coverage criteria; revisions reflected in policy history.

Higher-risk category prompting repeat testing and consideration of secondary testing, imaging, or biopsy

Alternate/variant rangesGuidelines sometimes reference 3–10 ng/mL or >4 ng/mL for secondary testing decisions

Include the following procedure codes on claims for PSA testing as referenced in the policy.

CPT 84152 — Prostate specific antigen (PSA); complexed (direct measurement)
CPT 84153 — Prostate specific antigen (PSA); total
CPT 84154 — Prostate specific antigen (PSA); free
HCPCS G0103 — Prostate cancer screening; prostate specific antigen test (PSA)

Step Therapy

Follow-up %fPSA after negative biopsy

Percent free PSA (%fPSA) is covered as a follow-up test when total PSA is elevated and an initial prostate biopsy was negative; frequency should be no more often than follow-up total PSA.

Use %fPSA only after an initial negative biopsy when total PSA remains elevated.
Do not perform %fPSA more frequently than follow-up total PSA testing.

Step Therapy

Repeat PSA and secondary workup before biopsy

Before proceeding to secondary biomarkers, imaging, or prostate biopsy for an elevated PSA (e.g., >3 ng/mL), repeat the PSA and consider mpMRI and validated biomarkers as part of the secondary workup.

Repeat PSA prior to secondary biomarker testing, imaging, or biopsy.
Consider multiparametric MRI (mpMRI) and biomarkers when deciding whether to perform biopsy; if mpMRI is negative, consider biomarkers and PSA density before forgoing biopsy.

Step Therapy

Step therapy: none specified

No step therapy requirements are specified in this section of the policy.

Documentation Required

Required clinical documentation (age, risk, prior PSA)

Clinical documentation must substantiate the member's age, risk status (e.g., African ancestry, germline mutations, suspicious family history), prior total PSA results, and the clinical indication for testing.

Record age and which coverage criterion applies (initial screening vs high-risk earlier screening).
Document prior total PSA values and DRE findings when applicable.
Document indication: screening, follow-up for elevated PSA, diagnostic evaluation, or monitoring.

Documentation Required

Required documentation: SDM, baseline PSA, risk status

Documentation should include evidence of shared decision-making, explicit recording of patient risk status (age, family history, race, germline mutations), baseline PSA values, and the planned retest interval per guideline-based thresholds.

Note shared decision-making discussion and patient preferences.
Record baseline PSA and planned repeat interval tied to PSA category (e.g., 2–4 years for PSA <1 ng/mL; 1–2 years for PSA 1–3 ng/mL).

Billing Rule

Lab validation and billed procedure codes

Labs must validate any laboratory-developed tests in-house under CLIA '88, and PSA-related tests referenced in coding include CPT 84152, 84153, 84154 and G0103 for screening.

Ensure LDTs are validated and performed in-house per CLIA '88.
Use CPT/HCPCS codes 84152, 84153, 84154 and G0103 when billing PSA tests as referenced.

Denial Risk

Not covered PSA variants — denial risk

Requests for percent free PSA as a first-line screening test, percent free or free-to-total PSA ratio for routine screening, and complexed PSA testing do not meet coverage criteria and may be denied.

Do not bill percent free PSA as a first-line screening test or for routine population screening.
Complexed PSA testing is listed as not meeting coverage criteria.

Denial Risk

Regulatory conflicts may trigger denial

If a conflict exists between this policy and applicable government (Medicare/Medicaid) coverage—such as an LCD or NCD—the government policy will govern and nonconcordant claims could be denied.

Check applicable Medicare/Medicaid LCDs/NCDs and state Medicaid policies; government determinations supersede this policy when discrepant.
Nonconcordant claims may be denied per the applicable government coverage.

Denial Risk

Conflicts with government coverage — follow government policy

When government coverage (Medicare/Medicaid) conflicts with this policy, the government policy will be used to make coverage determinations; follow the applicable LCD/NCD/state coverage rules.

Use the Medicare Coverage Database and relevant state Medicaid resources to confirm current government coverage.
Align claims and documentation with the governing government policy to avoid denials.

Prostate-specific antigen

percent free PSA (%fPSA)

%fPSA definitionPercent free PSA (%fPSA) is the proportion of unbound (free) PSA to total PSA used as a secondary test

FDA noteFDA approved %fPSA for early detection in individuals aged ≥50 years with non‑suspicious DRE and PSA 4–10 ng/mL (per NCCN discussion)

Clinical useOften used after an initial negative biopsy or to improve specificity and reduce unnecessary biopsies

PSA monitoring in treated or advanced disease

Monitoring interval (ADT / mHSPC)Obtain serial PSA measurements every 3–6 months after initiation of androgen deprivation therapy

Monitoring interval (nmCRPC)Obtain serial PSA measurements every 3–6 months and calculate PSA doubling time starting at castration-resistance

Surveillance imaging triggerIn patients without PSA progression or new symptoms, perform imaging at least annually (mCRPC guidance)

Beckman Coulter Prostate Health Index (phi)

What phi isThe Beckman Coulter Prostate Health Index (phi) is an IVDMIA calculated from p2PSA ([-2] proPSA), total PSA, and free PSA

FDA-cleared assayAccess® Hybritech® p2PSA assay (Beckman Coulter) is FDA approved to be used with total and free PSA to calculate phi (approved June 14, 2012)

Clinical rolePhi is cited as a multivariate index assay intended to improve early detection and aid secondary testing decisions